CONCOR 5 MG Israel - engelsk - Ministry of Health

concor 5 mg

merck serono ltd - bisoprolol fumarate - tablets - bisoprolol fumarate 5 mg - bisoprolol - - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.- hypertension- coronary heart disease (angina pectoris)

CONCOR 1.25 MG Israel - engelsk - Ministry of Health

concor 1.25 mg

merck serono ltd - bisoprolol fumarate - film coated tablets - bisoprolol fumarate 1.25 mg - bisoprolol - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function (ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.

CONCOR 2.5 MG Israel - engelsk - Ministry of Health

concor 2.5 mg

merck serono ltd - bisoprolol fumarate - film coated tablets - bisoprolol fumarate 2.5 mg - bisoprolol - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function (ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.

Concord Birth Trolley - Infant resuscitation table Australia - engelsk - Department of Health (Therapeutic Goods Administration)

concord birth trolley - infant resuscitation table

vicki partridge pty ltd - 36685 - infant resuscitation table - birth trolley, with mattress, which enables caregivers to deliver medical care to neonates immediately after birth.

CONCORD 300SC New Zealand - engelsk - Ministry for Primary Industries

concord 300sc

adria new zealand ltd - cymoxanil - cymoxanil 300 g/litre - fungicide

ZONEGRAN- zonisamide capsule USA - engelsk - NLM (National Library of Medicine)

zonegran- zonisamide capsule

concordia pharmaceuticals inc. - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide 25 mg - zonegran is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonegran is contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonegran has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.